Login to Your Account



$70M Up Front For Two Programs

Infinity, MedImmune Enter Deal With $500M Potential

By Randall Osborne


Tuesday, August 29, 2006
While MedImmune Inc. awaits word from the FDA on the supplemental biologics license application for its flu vaccine and seeks ways to pump sales of Synagis, the firm signed a potential $500 million deal with Infinity Pharmaceuticals Inc. focused on small-molecule cancer drugs targeting heat-shock protein 90 (Hsp90) and the Hedgehog cell-signaling pathway. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription